Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/3861
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorZERATI, Marcelo-
dc.contributor.authorLEITE, Katia R. M.-
dc.contributor.authorPONTES-JUNIOR, Jose-
dc.contributor.authorSEGRE, Cesar Camara-
dc.contributor.authorREIS, Sabrina Thalita-
dc.contributor.authorSROUGI, Miguel-
dc.contributor.authorDALL'OGLIO, Marcos Francisco-
dc.date.accessioned2014-01-28T22:16:05Z-
dc.date.available2014-01-28T22:16:05Z-
dc.date.issued2013-
dc.identifier.citationINTERNATIONAL BRAZ J UROL, v.39, n.4, p.484-492, 2013-
dc.identifier.issn1677-5538-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/3861-
dc.description.abstractIntroduction: The knowledge about the molecular biology of clear cell renal cell carcinoma (ccRCC) is evolving, and Carbonic Anhydrase type IX (CA-IX) has emerged as a potential prognostic marker in this challenging disease. However, most of the literature about CA-IX on ccRCC comes from series on metastatic cancer, with a lack of series on non-metastatic cancer. The objective is to evaluate the expression of CA-IX in a cohort of non-metastatic ccRCC, correlating with 1) overall survival, and 2) with established prognostic parameters (T stage, tumor size, Fuhrman nuclear grade, microvascular invasion and peri-renal fat invasion). Materials and Methods: This is a retrospective cohort study. We evaluated 95 patients with non-metastatic clear cell renal cell carcinoma, as to the expression of CA-IX. The analyzed parameters where: overall survival (OS), TNM stage, tumor size (TS), Fuhrman nuclear grade (FNG), microvascular invasion (MVI), peri-renal fat invasion (PFI). We utilized a custom built tissue microarray, and the immunoexpression was digitally quantified using the Photoshop (R) software. Results: The mean follow-up time was 7.9 years (range 1.9 to 19.5 years). The analysis of CA-IX expression against the selected prognostic parameters showed no correlation. The results are as follows: Overall survival (p = 0.790); T stage (p = 0.179); tumor size (p = 0.143); grouped Fuhrman nuclear grade (p = 0.598); microvascular invasion (p = 0.685), and peri-renal fat invasion (p = 0.104). Conclusion: Carbonic anhydrase type IX expression does not correlate with overall survival and conventional prognostic parameters in non-metastatic clear cell renal cell carcinoma.-
dc.description.sponsorshipFAPESP (State of Sao Paulo Agency for Research Support) [2008/52908-8]-
dc.language.isoeng-
dc.publisherBRAZILIAN SOC UROL-
dc.relation.ispartofInternational Braz J Urol-
dc.rightsopenAccess-
dc.subjectCarcinoma-
dc.subjectRenal Cell-
dc.subjectTissue Array Analysis-
dc.subjectImmunohistochemistry-
dc.subjectCarbonic Anhydrases-
dc.subject.otherinducible factor 1-alpha-
dc.subject.otherimage-analysis-
dc.subject.otherindependent predictor-
dc.subject.othermolecular markers-
dc.subject.otherprognostic value-
dc.subject.othertumor specimens-
dc.subject.otheradobe-photoshop-
dc.subject.otherbreast-cancer-
dc.subject.othergenetic-basis-
dc.subject.otherexpression-
dc.titleCarbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray-
dc.typearticle-
dc.rights.holderCopyright BRAZILIAN SOC UROL-
dc.identifier.doi10.1590/S1677-5538.IBJU.2013.04.05-
dc.identifier.pmid24054396-
dc.subject.wosUrology & Nephrology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage484-
hcfmusp.description.endpage492-
hcfmusp.description.issue4-
hcfmusp.description.volume39-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000327879200005-
hcfmusp.origem.id2-s2.0-84885340191-
hcfmusp.origem.idSCIELO:S1677-55382013000400484-
hcfmusp.publisher.cityRIO DE JANEIRO-
hcfmusp.publisher.countryBRAZIL-
hcfmusp.relation.referenceAtkins M, 2005, CLIN CANCER RES, V11, P3714, DOI 10.1158/1078-0432.CCR-04-2019-
hcfmusp.relation.referenceAtkins MB, 2009, CANCER, V115, P2327, DOI 10.1002/cncr.24231-
hcfmusp.relation.referenceBrunner J, 2000, MICROCIRCULATION, V7, P103, DOI 10.1038/sj.mn.7300094-
hcfmusp.relation.referenceBui MHT, 2003, CLIN CANCER RES, V9, P802-
hcfmusp.relation.referenceBui MHT, 2004, J UROLOGY, V171, P2461, DOI 10.1097/01.0000116444.08690.e2-
hcfmusp.relation.referenceChow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628-
hcfmusp.relation.referenceGavrielides MA, 2011, ARCH PATHOL LAB MED, V135, P233, DOI 10.1043/1543-2165-135.2.233-
hcfmusp.relation.referenceGNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85-
hcfmusp.relation.referenceGOTO M, 1992, PATHOL RES PRACT, V188, P433-
hcfmusp.relation.referenceHarris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704-
hcfmusp.relation.referenceHong YS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-246-
hcfmusp.relation.referenceHoos A, 2001, LAB INVEST, V81, P1331-
hcfmusp.relation.referenceJemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]-
hcfmusp.relation.referenceJemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI 10.3322/caac.20105-
hcfmusp.relation.referenceKarlsson C, 2009, CANCER EPIDEM BIOMAR, V18, P2014, DOI 10.1158/1055-9965.EPI-08-0743-
hcfmusp.relation.referenceKim HL, 2005, J UROLOGY, V173, P1496, DOI 10.1097/01.ju.0000154351.37249.f0-
hcfmusp.relation.referenceKlatte T, 2009, CANCER EPIDEM BIOMAR, V18, P894, DOI 10.1158/1055-9965.EPI-08-0786-
hcfmusp.relation.referenceKohlberger PD, 1996, AM J CLIN PATHOL, V105, P705-
hcfmusp.relation.referenceKononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844-
hcfmusp.relation.referenceLehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559-
hcfmusp.relation.referenceLehr HA, 1999, J HISTOCHEM CYTOCHEM, V47, P119-
hcfmusp.relation.referenceLeibovich BC, 2007, J CLIN ONCOL, V25, P4757, DOI 10.1200/JCO.2007.12.1087-
hcfmusp.relation.referenceLeppert JT, 2005, BJU INT, V96, P281, DOI 10.1111/j.1464-410X.2005.05615.x-
hcfmusp.relation.referenceLinehan WM, 2005, BJU INT, V95, P2, DOI 10.1111/j.1464-410X.2005.05189.x-
hcfmusp.relation.referenceLinehan WM, 2005, CANC PRINCIPLES PRAC, P1139-
hcfmusp.relation.referenceLinehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed-
hcfmusp.relation.referenceMaranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2-
hcfmusp.relation.referenceMasmoudi H, 2009, IEEE T MED IMAGING, V28, P916, DOI 10.1109/TMI.2009.2012901-
hcfmusp.relation.referenceMaxwell PH, 1999, NATURE, V399, P271-
hcfmusp.relation.referenceMofidi R, 2003, EUR J SURG ONCOL, V29, P20, DOI 10.1053/ejso.2002.1373-
hcfmusp.relation.referenceNovick A, 2002, CAMPBELLS UROLOGY, P2672-
hcfmusp.relation.referencePantuck AJ, 2003, CLIN CANCER RES, V9, P4641-
hcfmusp.relation.referencePastorekova S, 2006, ADV CLIN CHEM, V42, P167, DOI 10.1016/S0065-2423(06)42005-9-
hcfmusp.relation.referencePastorekova S, 2004, CANC THER, V2, P245-
hcfmusp.relation.referencePatard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055-
hcfmusp.relation.referenceSaad HA, 2008, CORNEA, V27, P818, DOI 10.1097/ICO.0b013e3181705ca2-
hcfmusp.relation.referenceSandlund J, 2007, BJU INT, V100, P556, DOI 10.1111/j.1464-410X.2007.07006.x-
hcfmusp.relation.referenceSemenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1-
hcfmusp.relation.referenceSoyupak B, 2005, UROL INT, V74, P68, DOI 10.1159/000082713-
hcfmusp.relation.referenceTorhorst J, 2001, AM J PATHOL, V159, P2249, DOI 10.1016/S0002-9440(10)63075-1-
hcfmusp.relation.referenceTunuguntla HSGR, 2008, J UROLOGY, V179, P2096, DOI 10.1016/j.juro.2008.01.083-
hcfmusp.relation.referenceWykoff CC, 2000, CANCER RES, V60, P7075-
hcfmusp.relation.referenceZhong H, 2000, CANCER RES, V60, P1541-
hcfmusp.relation.referenceZhong H, 1999, CANCER RES, V59, P5830-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipFAPESP-
hcfmusp.citation.scopus9-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCG
Departamento de Cirurgia - FM/MCG

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ZERATI_Carbonic_Anhydrase_IX_is_Not_a_Predictor_of_2013.PDFpublishedVersion (English)327.83 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.